DocGo Inc (DCGO)vsJohnson & Johnson (JNJ)
DCGO
DocGo Inc
$0.67
+15.31%
HEALTHCARE · Cap: $61.74M
JNJ
Johnson & Johnson
$260.86
+0.41%
HEALTHCARE · Cap: $614.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 32358% more annual revenue ($97.93B vs $301.71M). JNJ leads profitability with a 21.5% profit margin vs -62.2%. JNJ earns a higher WallStSmart Score of 57/100 (C).
DCGO
Hold36
out of 100
Grade: F
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.4%
Fair Value
$2.10
Current Price
$0.67
$1.43 discount
Margin of Safety
-87.3%
Fair Value
$139.75
Current Price
$260.86
$121.11 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -141.9% — below average capital efficiency
Revenue declined 21.3%
Moderate valuation
Expensive relative to growth rate
Earnings declined 0.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : DCGO
The strongest argument for DCGO centers on Price/Book, Debt/Equity.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bear Case : DCGO
The primary concerns for DCGO are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
DCGO profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.
DCGO carries more volatility with a beta of 0.99 — expect wider price swings.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 36/100), backed by strong 21.5% margins. DCGO offers better value entry with a 65.4% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DocGo Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
DocGo Inc. is a leading mobile healthcare service provider focused on enhancing patient accessibility and optimizing healthcare delivery through its cutting-edge logistics and telehealth solutions. The company specializes in urgent care, diagnostic testing, and health screenings, effectively addressing key healthcare challenges across diverse environments and significantly improving patient experiences. With a strong commitment to innovation and expanding access to healthcare, DocGo is well-positioned in the dynamic healthtech sector, making it an attractive investment opportunity for institutional investors interested in sustainable growth and impactful social contributions.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?